Literature DB >> 24657424

Prognostic significance of plasma copeptin detection compared with multiple biomarkers in intracerebral hemorrhage.

Wen-Hua Yu1, Wen-Hong Wang2, Xiao-Qiao Dong3, Quan Du1, Ding-Bo Yang1, Yong-Feng Shen1, Hao Wang1, Zu-Yong Zhang1, Qiang Zhu1, Zhi-Hao Che1, Qun-Jie Liu1, Li Jiang1, Yuan-Feng Du1.   

Abstract

BACKGROUND: Higher plasma copeptin concentrations have been associated with poor clinical outcomes after intracerebral hemorrhage. This study was designed to compare plasma concentrations of copeptin and other biomarkers like myelin basic protein, glial fibrillary astrocyte protein, S100B, neuron-specific enolase, phosphorylated axonal neurofilament subunit H, tau and ubiquitin carboxyl-terminal hydrolase L1 for analysis of their prognostic prediction.
METHODS: We measured plasma concentrations of these biomarkers in 118 healthy controls and in 118 acute patients with a comparison analysis for their prediction of 6-month mortality and unfavorable outcome (modified Rankin Scale score>2).
RESULTS: Plasma concentrations of these biomarkers were statistically significantly higher in all patients than in healthy controls, in non-survivors than in survivors and in patients with unfavorable outcome than with favorable outcome. Areas under receiver operating characteristic curves of plasma concentrations of these biomarkers were similar to those of the National Institute of Health Stroke Scale score for prognostic prediction. Plasma copeptin concentration statistically significantly improved the prognostic predictive value of the National Institute of Health Stroke Scale score, but other biomarkers did not.
CONCLUSIONS: Copeptin may help in the prediction of long-term clinical outcomes after intracerebral hemorrhage.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarkers; Copeptin; Intracerebral hemorrhage; Prognosis

Mesh:

Substances:

Year:  2014        PMID: 24657424     DOI: 10.1016/j.cca.2014.03.014

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  6 in total

1.  Plasma copeptin for short term risk stratification in acute pulmonary embolism.

Authors:  Anna Wyzgał; Marcin Koć; Szymon Pacho; Maksymilian Bielecki; Radosław Wawrzyniak; Maciej Kostrubiec; Michał Ciurzyński; Katarzyna Kurnicka; Sylwia Goliszek; Marzena Paczyńska; Piotr Palczewski; Piotr Pruszczyk
Journal:  J Thromb Thrombolysis       Date:  2016-05       Impact factor: 2.300

Review 2.  Association Between Circulating Copeptin Level and Mortality Risk in Patients with Intracerebral Hemorrhage: a Systemic Review and Meta-Analysis.

Authors:  Ruoyu Zhang; Jin Liu; Ying Zhang; Qiang Liu; Tianlang Li; Lei Cheng
Journal:  Mol Neurobiol       Date:  2016-01-05       Impact factor: 5.590

Review 3.  Prognostic role of copeptin after stroke: A systematic review and meta-analysis of observational studies.

Authors:  Kyu-Sun Choi; Hyun Jung Kim; Hyoung-Joon Chun; Jae Min Kim; Hyeong-Joong Yi; Jin-Hwan Cheong; Choong-Hyun Kim; Suck-Jun Oh; Yong Ko; Young-Soo Kim; Koang-Hum Bak; Je-Il Ryu; Wonhee Kim; Taeho Lim; Hyeong Sik Ahn; Il Min Ahn; Seon-Heui Lee
Journal:  Sci Rep       Date:  2015-06-29       Impact factor: 4.379

Review 4.  Copeptin testing in acute myocardial infarction: ready for routine use?

Authors:  Sebastian Johannes Reinstadler; Gert Klug; Hans-Josef Feistritzer; Bernhard Metzler; Johannes Mair
Journal:  Dis Markers       Date:  2015-04-16       Impact factor: 3.434

5.  Elevated Serum Levels of NSE and S-100β Correlate with Increased Risk of Acute Cerebral Infarction in Asian Populations.

Authors:  Ke Li; Jianjun Jia; ZhenFu Wang; ShanChun Zhang
Journal:  Med Sci Monit       Date:  2015-06-30

6.  Serum neurofilament light and tau as prognostic markers for all-cause mortality in the elderly general population-an analysis from the MEMO study.

Authors:  Nicole Rübsamen; Aleksandra Maceski; David Leppert; Pascal Benkert; Jens Kuhle; Heinz Wiendl; Annette Peters; André Karch; Klaus Berger
Journal:  BMC Med       Date:  2021-02-15       Impact factor: 8.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.